Medlab 2025
)
This 24th edition promises to be a landmark event, spotlighting cutting-edge advancements and sustainable practices in laboratory medicine. Over 800+ exhibitors from 40+ countries, will converge to unveil the latest innovations and technologies across 8 dynamic product categories.
Oxford Nanopore will be located at booth Z6.E29, and will host an Industry Workshop on Wednesday 5 February, 2025. Session will be held in the Oman Room
Date: Wednesday 5 February, 2025
Time: 14.00-17.30
Location: Oman Room
Description:
Join Oxford Nanopore Technologies at MedLab 2025 to explore the future of clinical research. This hands-on workshop will highlight the readiness of nanopore sequencing for clinical applications. Attendees can look forward to engaging expert talks, live demonstrations of the technology, and insightful discussions on bioinformatics workflows. If you are dedicated to advancing diagnostics, genomics, or precision medicine, this session will provide you with the practical knowledge and innovative strategies essential for enhancing your research capabilities.
For more information, please refer to the conference program.
Agenda
14:00-17:30 | Talk title | Speaker |
|---|---|---|
14:00-14:15 | ONT Welcome & Introduction | Walaa Mohamed Oxford Nanopore Technologies |
14:15-14:45 | ONT Technical Update | Jawahar Swaminathanr, Oxford Nanopore Technologies |
14:45-15:15 | Unlocking clinical genomics with Oxford Nanopore Technologies whole-genome sequencing: A comparative study with short-read technologies | Javier Quilez, M42, Abu Dhabi |
15:15-15:45 | Talk title: Streamlining Carrier Screening Insights with Long-Range PCR & Long-Read Sequencing | Yiannis Demetriades, Asuragen |
15:45-16:15 | Networking Break | |
16:15-16:45 | ONT demo | Ashan Musafer, Oxford Nanopore Technologies |
16:45-17:15 | Nanopore end-to-end protocols for infectious diseases applications | Justin O'Grady, Oxford Nanopore Technologies |
17:15-17:30 | ONT close | Walaa Mohamed Oxford Nanopore Technologies |
Industry workshop speakers
)
Walaa Mohamed, Clinical Sales Specialist, Oxford Nanopore TechnologiesWalaa brings over a decade of expertise in genetics and genomics research, with a strong focus on identifying genetic variants linked to rare disorders in the Arab population. She has been with Oxford Nanopore Technologies for over 2 years, initially serving as a Senior Field Scientist within the Genomics Consultant Solution team, and recently transitioning to the Clinical Specialist team.
Prior to joining Oxford Nanopore, Walaa played a pivotal role as an R&D Scientist in the validation phase of the Emirati Genome Project.
Walaa earned her Ph.D. in Human Genetics from the Autonomous University of Barcelona, where her research centered on novel mutations causing hearing loss. Her extensive professional and academic background highlights her dedication to advancing clinical genomics and her significant contributions to the field.
)
Yiannis Demetriades, Product Manager, EMEA, AsuragenYiannis is a skilled product marketing professional with a background in medical writing and biotech brand management. Currently a product marketing manager at Bio-Techne, he has successfully driven brand awareness, marketing campaigns and stakeholder engagement in the European market, particularly in genetics and breast oncology. With prior experience in medical writing, he has developed high-quality scientific content and facilitated key industry events. Yiannis holds an MSc in stem cells and regenerative therapies from Kings College London and a BSc from Imperial College London. Fluent in multiple languages, he’s passionate about strategic communication, cross-functional collaboration, and advocating for innovative medical solutions.
)
Javier Quilez, Associate Director, Bioinformatics, M42, Abu Dhabi, United Arab EmiratesMy name is Javier Quilez and I am Associate Director of Bioinformatics at M42, where I have worked the last 4+ years driving the Emirati Genome Program as well as other large-scale sequencing projects. My career started with 10+ years in academia for my PhD and post-doctoral studies working on population, evolutionary and structural genomics. Prior to joining M42, I worked at Clarivate consulting for pharma and biotech companies on bioinformatics and drug discovery. I really enjoy opportunities like this event to communicate technical work to a broader audience
)
Justin O'Grady, Senior Director, Oxford Nanopore TechnologiesProf Justin O'Grady gained his BSc, MSc and PhD in microbiology and infectious diseases at the National University of Ireland Galway (NUIG). He remained at NUIG for his first post-doc, focussing on foodborne pathogens. This was followed by a two-year stint in industry (Beckman Coulter) developing real-time PCR based tests for infectious diseases. Prof O’Grady then returned to academia, taking a post-doc position at University College London on TB diagnostics. In January 2013 he was appointed Assistant Professor in Medical Microbiology at the University of East Anglia (Norwich, UK), was promoted to Associate Professor in August 2016 and promoted to Professor in January 2021. He was seconded to the University of Cambridge during the COVID pandemic as Deputy Director of COG-UK, to help lead the UK’s SARS-CoV-2 sequencing effort. He then joined Oxford Nanopore Technologies as Senior Director of Translational Applications in June 2021. His research continues to focus on the development of rapid diagnostic tests, to maximise community and patient benefit.
In this presentation I will talk about recent developments in sequencing and analysis technologies at Oxford Nanopore. Following a short introduction to the Nanopore sequencing method, I will talk about the various applications and pipelines in production and those coming down the line including human genetics (Germline and Cancer) as well as pipelines for single cell, direct RNA and metagenomics.
In this presentation I will talk about recent developments in sequencing and analysis technologies at Oxford Nanopore. Following a short introduction to the Nanopore sequencing method, I will talk about the various applications and pipelines in production and those coming down the line including human genetics (Germline and Cancer) as well as pipelines for single cell, direct RNA and metagenomics.
)
Jawahar Swaminathan, Director of Informatics, Oxford Nanopore Technologies
